AstraZeneca (AZN) Shares Decline After Recruitment Paused in Head and Neck Cancer Trial

October 27, 2016 10:58 AM EDT

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

(Updated - October 27, 2016 11:44 AM EDT)

(Updated - October 27, 2016 11:13 and 11:27 AM EDT)

AstraZeneca (NYSE: AZN) declined Thursday, falling over 4% intraday. Chatter suggested weakness was related to a halt in recruitment for its trial evaluating its IO combo in head and neck cancer.

Update:

Recruitment was suspended in its study of MEDI4736 (Durvaluma) Monotherapy in Combination with Tremelimumab, according to clinicaltrials.gov. In a statement to Bloomberg an AstraZeneca spokesperson confirmed it paused enrollment for some Durvalumab trials over bleeding incidents.

From Clinicaltrials.gov:

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

This study has suspended participant recruitment.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT02369874
First received: February 18, 2015
Last updated: October 20, 2016
Last verified: October 2016


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA, Hot Corp. News, Hot FDA News, Trader Talk

Add Your Comment